Joel M Cherlow1, Dennis W W Shaw2, Linda R Margraf3, Daniel C Bowers4, Jie Huang5, Maryam Fouladi6, Arzu Onar-Thomas5, Tianni Zhou7, Ian F Pollack8, Amar Gajjar9, Sandy K Kessel10, Patricia L Cullen11, Kevin McMullen12, John C Wellons13, Thomas E Merchant14. 1. Department of Radiation Oncology, MemorialCare Long Beach Medical Center Long Beach, California. 2. Department of Diagnostic Imaging, Seattle Children's Hospital, Seattle, Washington. 3. Department of Pathology, Cook Children's Medical Center, Ft. Worth, Texas. 4. Department of Pediatrics, UT Southwestern Medical School, Dallas, Texas. 5. Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee. 6. Department of Hematology/Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. 7. Department of Mathematics, California State University, Long Beach, California. 8. Department of Neurosurgery, Children's Hospital of Pittsburgh of UMPC, Pittsburgh, Pennsylvania. 9. Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee. 10. Imaging and Radiation Oncology Core Rhode Island, Lincoln, Rhode Island. 11. Rueckert-Hartman College for Health Professions, Regis University, Denver, Colorado. 12. Department of Radiation Oncology, Columbus Regional Health, Columbus, Indiana. 13. Department of Neurosurgery, Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee. 14. Department of Radiation Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee. Electronic address: thomas.merchant@stjude.org.
Abstract
PURPOSE: To determine the rate of marginal relapse, progression-free survival (PFS), and overall survival (OS) in patients with pediatric low-grade glioma (PLGG) treated with conformal radiation therapy (CRT) with a clinical target volume (CTV) margin of 5 mm in the Children's Oncology Group trial ACNS0221. METHODS AND MATERIALS: Patients aged 3 to 21 years with unresectable progressive, recurrent, or residual PLGG were eligible for this study. Patients younger than 10 years were required to have received at least 1 chemotherapy course. Patients with neurofibromatosis type I were not eligible. All patients underwent magnetic resonance imaging-based planning and received 54 Gy CRT in 30 fractions with a 5-mm CTV margin. RESULTS: Of 85 eligible patients (median age, 13.6 years) treated between March 2006 and December 2010, 14 were younger than 10 years and 36 received prior chemotherapy. Sixty-six had pilocytic astrocytoma, 15 had other histologic subtypes, and 4 had unbiopsied chiasmatic lesions. Events included 23 relapses (19 central, 4 distant, and no marginal) and 7 deaths. At a median follow-up of 5.15 years, 5-year PFS was 71% ± 6% and OS was 93% ± 4%. Male sex (P = .068) and large tumor size (P = .050) trended toward significance for association with decreased PFS. Age, histology, tumor location, time between diagnosis and study entry, and MIB-1 status were not associated with PFS. OS was negatively associated with male sex (P = .064), non-pilocytic astrocytoma histology (P = .010), and large tumor size (P = .0089). CONCLUSIONS: For patients with PLGG, CRT with a CTV margin of 5 mm yields an acceptable PFS and does not lead to a high rate of marginal relapse.
PURPOSE: To determine the rate of marginal relapse, progression-free survival (PFS), and overall survival (OS) in patients with pediatric low-grade glioma (PLGG) treated with conformal radiation therapy (CRT) with a clinical target volume (CTV) margin of 5 mm in the Children's Oncology Group trial ACNS0221. METHODS AND MATERIALS: Patients aged 3 to 21 years with unresectable progressive, recurrent, or residual PLGG were eligible for this study. Patients younger than 10 years were required to have received at least 1 chemotherapy course. Patients with neurofibromatosis type I were not eligible. All patients underwent magnetic resonance imaging-based planning and received 54 Gy CRT in 30 fractions with a 5-mm CTV margin. RESULTS: Of 85 eligible patients (median age, 13.6 years) treated between March 2006 and December 2010, 14 were younger than 10 years and 36 received prior chemotherapy. Sixty-six had pilocytic astrocytoma, 15 had other histologic subtypes, and 4 had unbiopsied chiasmatic lesions. Events included 23 relapses (19 central, 4 distant, and no marginal) and 7 deaths. At a median follow-up of 5.15 years, 5-year PFS was 71% ± 6% and OS was 93% ± 4%. Male sex (P = .068) and large tumor size (P = .050) trended toward significance for association with decreased PFS. Age, histology, tumor location, time between diagnosis and study entry, and MIB-1 status were not associated with PFS. OS was negatively associated with male sex (P = .064), non-pilocytic astrocytoma histology (P = .010), and large tumor size (P = .0089). CONCLUSIONS: For patients with PLGG, CRT with a CTV margin of 5 mm yields an acceptable PFS and does not lead to a high rate of marginal relapse.
Authors: Karen J Marcus; Liliana Goumnerova; Amy L Billett; Beverly Lavally; R Michael Scott; Karyn Bishop; Rhongi Xu; Tina Young Poussaint; Mark Kieran; Hanne Kooy; Scott L Pomeroy; Nancy J Tarbell Journal: Int J Radiat Oncol Biol Phys Date: 2005-02-01 Impact factor: 7.038
Authors: Jeffrey H Wisoff; Robert A Sanford; Linda A Heier; Richard Sposto; Peter C Burger; Allan J Yates; Emiko J Holmes; Larry E Kun Journal: Neurosurgery Date: 2011-06 Impact factor: 4.654
Authors: Sheema Chawla; David N Korones; Michael T Milano; Ali Hussain; Abdel R Hussien; Ann G Muhs; Manisha Mangla; Howard Silberstein; Sven Ekholm; Louis S Constine Journal: J Neurooncol Date: 2012-01-12 Impact factor: 4.130
Authors: Eugen B Hug; Marc W Muenter; John O Archambeau; Alexander DeVries; Boleslaw Liwnicz; Lilia N Loredo; Roger I Grove; Jerry D Slater Journal: Strahlenther Onkol Date: 2002-01 Impact factor: 3.621
Authors: Rahul Krishnatry; Nataliya Zhukova; Ana S Guerreiro Stucklin; Jason D Pole; Matthew Mistry; Iris Fried; Vijay Ramaswamy; Ute Bartels; Annie Huang; Normand Laperriere; Peter Dirks; Paul C Nathan; Mark Greenberg; David Malkin; Cynthia Hawkins; Pratiti Bandopadhayay; Mark W Kieran; Peter E Manley; Eric Bouffet; Uri Tabori Journal: Cancer Date: 2016-03-10 Impact factor: 6.860
Authors: Thomas E Merchant; Heather M Conklin; Shengjie Wu; Robert H Lustig; Xiaoping Xiong Journal: J Clin Oncol Date: 2009-07-06 Impact factor: 44.544
Authors: Matthew W Parsons; Nicholas S Whipple; Matthew M Poppe; Joe S Mendez; Donald M Cannon; Lindsay M Burt Journal: J Neurooncol Date: 2020-10-31 Impact factor: 4.130
Authors: Sahaja Acharya; Jo-Fen Liu; Ruth G Tatevossian; Jason Chiang; Ibrahim Qaddoumi; Amar Gajjar; David Walker; Julie H Harreld; Thomas E Merchant; David W Ellison Journal: Neuro Oncol Date: 2020-08-17 Impact factor: 12.300
Authors: Liana Nobre; Michal Zapotocky; Vijay Ramaswamy; Scott Ryall; Julie Bennett; Daniel Alderete; Julia Balaguer Guill; Lorena Baroni; Ute Bartels; Abhishek Bavle; Miriam Bornhorst; Daniel R Boue; Adela Canete; Murali Chintagumpala; Scott L Coven; Ofelia Cruz; Sonika Dahiya; Peter Dirks; Ira J Dunkel; David Eisenstat; Cecile Faure Conter; Elizabeth Finch; Jonathan L Finlay; Didier Frappaz; Maria Luisa Garre; Karen Gauvain; Anne Grete Bechensteen; Jordan R Hansford; Inga Harting; Peter Hauser; Lili-Naz Hazrati; Annie Huang; Sarah G Injac; Valentina Iurilli; Matthias Karajannis; Gurcharanjeet Kaur; Martin Kyncl; Lenka Krskova; Normand Laperriere; Valerie Larouche; Alvaro Lassaletta; Sarah Leary; Frank Lin; Samantha Mascelli; Tara McKeown; Till Milde; Andres Morales La Madrid; Giovanni Morana; Helena Morse; Naureen Mushtaq; Diana S Osorio; Roger Packer; Zdenek Pavelka; Eduardo Quiroga-Cantero; James Rutka; Magnus Sabel; Duarte Salgado; Palma Solano; Jaroslav Sterba; Jack Su; David Sumerauer; Michael D Taylor; Helen Toledano; Derek S Tsang; Mariana Valente Fernandes; Frank van Landeghem; Cornelis M van Tilburg; Bev Wilson; Olaf Witt; Josef Zamecnik; Eric Bouffet; Cynthia Hawkins; Uri Tabori Journal: JCO Precis Oncol Date: 2020-05-20
Authors: Paul Rogowski; Christian Trapp; Rieke von Bestenbostel; Chukwuka Eze; Ute Ganswindt; Minglun Li; Marcus Unterrainer; Mathias J Zacherl; Harun Ilhan; Leonie Beyer; Alexander Kretschmer; Peter Bartenstein; Christian Stief; Claus Belka; Nina-Sophie Schmidt-Hegemann Journal: Eur J Nucl Med Mol Imaging Date: 2021-10-10 Impact factor: 9.236